Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione

Cancer Research

Volumn 62, Issue 8, 2002, Pages 2332-2336

  Geroni, Cristina ^c   Marchini, Sergio ^a   Cozzi, Paolo ^c   Galliera, Emanuela ^a   Ragg, Enzio ^b   Colombo, Tina ^a   Battaglia, Rosangela ^c   Howard, Martin ^c   D’Incalci, Maurizio ^a   Broggini, Massimo ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Pharmacia Corp   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BROSTALLICIN; BUTHIONINE SULFOXIMINE; DISTAMYCIN A; GLUTATHIONE; MELPHALAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW TOXICITY; BREAST CARCINOMA; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG BINDING; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; FEMALE; HUMAN; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CANCER; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG SYNERGISM; FEMALE; GLUTATHIONE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; GUANIDINES; HUMANS; ISOENZYMES; LEUKEMIA L1210; MICE; MICE, NUDE; OVARIAN NEOPLASMS; PLASMIDS; PYRROLES; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0037089552     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. DNA minor groove binding ligands: A new class of anticancer agents
2. DNA-minor-groove alkylators, a new class of anticancer agents
3. Development of distamycin-related DNA binding anticancer drugs
4. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days
5. Phase I study of adozelesin administered by 24-hour continuous intravenous infusion
6. Phase I trial of bizelesin using a single bolus infusion given every 28 days in patients with advanced cancer
7. Selective DNA interaction of the novel distamycin derivative FCE 24517
8. Sequence-specific cleavage of DNA by N-bromoacetyldistamycin. Product and kinetic analyses
9. Phase I study of the novel distamycin derivative tallimustine (FCE 24517)
10. Distamycin A derivative. FCE 24517: A Phase I study in solid tumors
11. Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells
12. p53-independent caspase-mediated apoptosis in human leukaemic cells is induced by a DNA minor groove binder with antineoplastic activity
13. α-bromoacryloyl derivative of distamycin A (PNU 151807): A new noncovalent minor groove DNA binder with antineoplastic activity
14. Cytotoxic halogenoacrylic derivatives of distamycin A
15. Recent outcome in the field of distamycin-derived minor groove binders
16. Antitumor activity of PNU-166196, a novel DNA minor groove binder selected for clinical development
17. Phase I study of PNU-166196 given on a weekly basis
18. Phase I study of PNU-166196, a novel DNA minor groove binder (MGB) with enhanced activity in tumor models expressing high glutathione (GSH) levels, administered to patients (Pts) with advanced cancer
19. PNU-166196, a novel antitumor agent with enhanced activity in tumors expressing high glutathione and/or glutathione S-transferase levels
20. Multidrug resistance in cells transfected with human genes encoding a variant P-glycoprotein and glutathione S-transferase-π
21. Glutathione S-transferase in chemotherapy resistance and in carcinogenesis
22. Importance of glutathione and associated enzymes in drug response
23. Glutathione transferases and cancer
24. Glutathione S-transferases: Biomarkers of cancer risk and chemopreventive response
25. The glutathione S-transferase supergene family: Regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance
26. Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors
27. Specific expression of glutathione S-transferase π forms in (pre)neo-plastic tissues: Their properties and functions
28. Elevation of π class glutathione S-transferase activity in human breast cancer cells by transfection of the GST π gene and its effect on sensitivity to toxins
29. Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression
30. Intracellular glutathione heterogeneity in L1210 murine leukemia sublines made resistant to DNA-interacting antineoplastic agents
31. Glutathione S-transferase activity in epithelial ovarian cancer: Association with response to chemotherapy and disease outcome
32. Glutathione S-transferase act as isomerases in isomerization of 13-cis-retinoic acid to all-trans-retinoic acid in vitro
33. Multidrug resistance
34. π-class glutathione S-transferase: Regulation and function
35. Glutathione S-transferase and drug resistance
36. Differential expression of drug resistance genes and chemosensitivity in glial cell lineages correlate with differential response of oligodendrogliomas and astrocytomas to chemotherapy
37. In vivo characterization and modulation of the glutathione/glutathione S-transferase system in cancer patients
38. Altered expression of resistance associated genes in hepatoblastoma xenografts incorporated into mice following treatment with adriamycin or cisplatin
39. Acute changes in liver gene expression in the N-nitrosodiethylamine-treated rat